BYL719, which is orally bioavailable, demonstrated a good safety profile in humans, and has been shown to be clinically effective in patients with PIK3CA‐related overgrowth syndrome (PROS) and patients with PIK3CA‐altered solid tumors (Juric et al, 2018; Venot et al, 2018). Here, PIK3CA is linked to overgrowth syndrome.